Wire · regulatory
FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The US FDA is holding a public hearing to gather feedback on therapeutic use of psychedelic drugs, advancing regulatory clarity and safety standards for these treatments as part of an accelerated development push initiated under the Trump administration.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 14 Sep 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You face a new regulatory window as the FDA shapes psychedelic drug rules for clinical use with clear safety and access standards. This is your chance to engage early on training, screening, and reimbursement processes critical for market entry.
◆ Coverage
3 sources · first reported 14 Sep 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics